Jefferies Group’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-33,500
Closed -$7.27M 2186
2021
Q1
$7.27M Sell
33,500
-176,300
-84% -$33.1M 0.06% 267
2020
Q4
$24.2M Sell
209,800
-15,100
-7% -$1.69M 0.19% 81
2020
Q3
$21.9M Sell
224,900
-3,900
-2% -$449K 0.24% 53
2020
Q2
$28.1K Buy
228,800
+2,400
+1% +$272K 0.33% 34
2020
Q1
$19.8M Buy
226,400
+26,300
+13% +$2.79M 0.22% 67
2019
Q4
$20.9M Buy
200,100
+98,300
+97% +$11M 0.16% 106
2019
Q3
$11.7M Buy
101,800
+4,600
+5% +$698K 0.09% 174
2019
Q2
$16.8M Sell
97,200
-11,000
-10% -$1.9M 0.12% 123
2019
Q1
$18.2M Buy
108,200
+96,000
+787% +$14.3M 0.15% 93
2018
Q4
$1.19M Sell
12,200
-5,800
-32% -$761K 0.01% 1073
2018
Q3
$3.11M Buy
+18,000
New +$2.6M 0.02% 772
2016
Q2
Sell
-44,600
Closed -$3.22M 2542
2016
Q1
$3.22M Buy
+44,600
New +$2.45M 0.02% 649

Other funds holding GWPH

Jefferies Group's GWPH Position: Q2 2021 in Review

Jefferies Group sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q2 2021, closing a stake of 21,618 shares — an estimated $4.69M sold.

Jefferies Group first reported a position in GWPH in Q1 2016 and held it in 14 quarters. The position peaked at $11.2M in Q1 2020. 1 fund tracked by Wall St. Rank holds GWPH as of Q2 2021.

  • Jefferies Group reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 21,618 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2021, an estimated $4.69M.
  • Jefferies Group first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q1 2016 and held it in 14 quarters.
  • Jefferies Group's GW Pharmaceuticals Plc American Depositary Shares position peaked at $11.2M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.